(Reuters) - TORONTO, July 24 - Neurochem Inc. said on Tuesday the U.S. Food and Drug Administration has designated its tramiprosate treatment as a fast-track product for the treatment of Alzheimer's disease.
The biotechnology company said it planned to meet with the FDA in August to discuss its Phase 3 program and provide an update on North American Phase 3 clinical trials.
Read more at Reuters.com Government Filings News
The biotechnology company said it planned to meet with the FDA in August to discuss its Phase 3 program and provide an update on North American Phase 3 clinical trials.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment